Veracyte Stock Analysis

VCYT Stock  USD 22.88  0.52  2.22%   
Veracyte is undervalued with Real Value of 27.46 and Target Price of 32.67. The main objective of Veracyte stock analysis is to determine its intrinsic value, which is an estimate of what Veracyte is worth, separate from its market price. There are two main types of Veracyte's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Veracyte's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Veracyte's stock to identify patterns and trends that may indicate its future price movements.
The Veracyte stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Veracyte is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Veracyte Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Veracyte's ongoing operational relationships across important fundamental and technical indicators.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Veracyte. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing.
For more information on how to buy Veracyte Stock please use our How to Invest in Veracyte guide.

Veracyte Stock Analysis Notes

About 99.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 1.45. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Veracyte recorded a loss per share of 0.93. The entity had not issued any dividends in recent years. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis Prosigna Breast Cancer Assay for breast cancer diagnosis Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis and Immunoscore Colon Cancer test for colon cancer diagnosis. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California. Veracyte operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 761 people. For more information please call Bonnie Anderson at 650 243 6300 or visit

Veracyte Quarterly Total Revenue

96.84 Million

Veracyte Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Veracyte's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Veracyte or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Veracyte generated a negative expected return over the last 90 days
The company reported the previous year's revenue of 361.05 M. Net Loss for the year was (74.4 M) with profit before overhead, payroll, taxes, and interest of 194.95 M.
Over 99.0% of the company outstanding shares are owned by institutional investors
Latest headline from Veracyte, Inc. Shares Bought by Russell Investments Group Ltd. - Defense World

Veracyte Upcoming and Recent Events

Earnings reports are used by Veracyte to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Veracyte previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
28th of February 2024
Upcoming Quarterly Report
2nd of May 2024
Next Financial Report
31st of December 2023
Next Fiscal Quarter End
28th of February 2024
Next Fiscal Year End
30th of September 2023
Last Quarter Report
31st of December 2022
Last Financial Announcement

Veracyte Largest EPS Surprises

Earnings surprises can significantly impact Veracyte's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Veracyte Environmental, Social, and Governance (ESG) Scores

Veracyte's ESG score is a quantitative measure that evaluates Veracyte's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Veracyte's operations that may have significant financial implications and affect Veracyte's stock price as well as guide investors towards more socially responsible investments.

Veracyte Thematic Classifications

In addition to having Veracyte stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Healthcare Idea
USA Equities from Healthcare industry as classified by Fama & French

Veracyte Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Veracyte is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Veracyte backward and forwards among themselves. Veracyte's institutional investor refers to the entity that pools money to purchase Veracyte's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Champlain Investment Partners, Llc2023-12-31
2.2 M
Geode Capital Management, Llc2023-12-31
1.6 M
Gw&k Investment Management, Llc2023-12-31
1.4 M
Nuveen Asset Management, Llc2023-12-31
Northern Trust Corp2023-12-31
979.8 K
Fisher Asset Management, Llc2023-12-31
875.2 K
Granite Investment Partners, Llc2023-12-31
873.3 K
Bank Of America Corp2023-12-31
839.5 K
New York State Common Retirement Fund2023-12-31
837.5 K
Blackrock Inc2023-12-31
7.2 M
Vanguard Group Inc2023-12-31
7.1 M
Note, although Veracyte's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Veracyte Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.75 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Veracyte's market, we take the total number of its shares issued and multiply it by Veracyte's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Veracyte Profitablity

Veracyte's profitability indicators refer to fundamental financial ratios that showcase Veracyte's ability to generate income relative to its revenue or operating costs. If, let's say, Veracyte is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Veracyte's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Veracyte's profitability requires more research than a typical breakdown of Veracyte's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (0.18) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.02 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.02.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.21)(0.23)
Return On Capital Employed(0.01)(0.01)
Return On Assets(0.07)(0.07)
Return On Equity(0.07)(0.07)

Management Efficiency

Return On Tangible Assets is likely to drop to -0.23 in 2024. Return On Capital Employed is likely to drop to -0.01 in 2024. At this time, Veracyte's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 1.2 B in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 19.6 M in 2024. Veracyte's management efficiency ratios could be used to measure how well Veracyte manages its routine affairs as well as how well it operates its assets and liabilities.
Last ReportedProjected for Next Year
Book Value Per Share 14.37  15.09 
Net Current Asset Value 0.00  0.00 
Tangible Asset Value 0.00  0.00 
Tangible Book Value Per Share 3.48  2.50 
Enterprise Value Over EBITDA 118.65  124.59 
Price Book Value Ratio 1.91  1.82 
Enterprise Value Multiple 118.65  124.59 
Price Fair Value 1.91  1.82 
Enterprise Value1.8 B1.9 B
The analysis of Veracyte's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Veracyte's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Veracyte Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.

Technical Drivers

As of the 18th of May 2024, Veracyte has the Coefficient Of Variation of (1,997), variance of 6.91, and Risk Adjusted Performance of (0.02). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Veracyte, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We have analyzed and interpolated thirteen technical drivers for Veracyte, which can be compared to its competition. Please validate Veracyte market risk adjusted performance and treynor ratio to decide if Veracyte is priced more or less accurately, providing market reflects its prevalent price of 22.88 per share. Given that Veracyte has information ratio of (0.09), we advise you to double-check Veracyte's current market performance to make sure the company can sustain itself at a future point.

Veracyte Price Movement Analysis

Execute Study
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Veracyte middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Veracyte. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Veracyte Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Veracyte insiders, such as employees or executives, is commonly permitted as long as it does not rely on Veracyte's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Veracyte insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Veracyte Predictive Daily Indicators

Veracyte intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Veracyte stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Veracyte Corporate Filings

8th of May 2024
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
7th of May 2024
Report filed with the SEC to announce major events that shareholders should know about
25th of April 2024
Other Reports
17th of April 2024
An amendment to a previously filed Form 8-K
2nd of April 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
22nd of March 2024
Other Reports
19th of March 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
8th of March 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities

Veracyte Forecast Models

Veracyte's time-series forecasting models are one of many Veracyte's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Veracyte's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Veracyte Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Veracyte prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Veracyte shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Veracyte. By using and applying Veracyte Stock analysis, traders can create a robust methodology for identifying Veracyte entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(0.21)(0.22)
Operating Profit Margin(0.03)(0.04)
Net Loss(0.21)(0.22)
Gross Profit Margin 0.62  0.42 

Current Veracyte Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Veracyte analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Veracyte analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Veracyte current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Veracyte analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Veracyte stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Veracyte, talking to its executives and customers, or listening to Veracyte conference calls.
Veracyte Analyst Advice Details

Veracyte Stock Analysis Indicators

Veracyte stock analysis indicators help investors evaluate how Veracyte stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Veracyte shares will generate the highest return on investment. By understating and applying Veracyte stock analysis, traders can identify Veracyte position entry and exit signals to maximize returns.
Begin Period Cash Flow154.2 M
Common Stock Shares Outstanding72.6 M
Total Stockholder EquityB
Tax Provision374 K
Property Plant And Equipment Net30.9 M
Cash And Short Term Investments216.5 M
Cash216.5 M
Accounts Payable12.9 M
Net Debt-203.8 M
50 Day M A20.9344
Total Current Liabilities61.2 M
Other Operating Expenses373.1 M
Non Current Assets Total852.2 M
Non Currrent Assets OtherM
Stock Based Compensation33.1 M
When determining whether Veracyte is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Veracyte Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Veracyte Stock. Highlighted below are key reports to facilitate an investment decision about Veracyte Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Veracyte. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing.
For more information on how to buy Veracyte Stock please use our How to Invest in Veracyte guide.
You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.

Complementary Tools for Veracyte Stock analysis

When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Bonds Directory
Find actively traded corporate debentures issued by US companies
Is Veracyte's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Veracyte. If investors know Veracyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Veracyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
Revenue Per Share
Quarterly Revenue Growth
Return On Assets
Return On Equity
The market value of Veracyte is measured differently than its book value, which is the value of Veracyte that is recorded on the company's balance sheet. Investors also form their own opinion of Veracyte's value that differs from its market value or its book value, called intrinsic value, which is Veracyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Veracyte's market value can be influenced by many factors that don't directly affect Veracyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Veracyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Veracyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Veracyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.